Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Parkinson Disease: HELP
Articles by Ting-Ting Wu
Based on 4 articles published since 2010
(Why 4 articles?)

Between 2010 and 2020, Ting Wu wrote the following 4 articles about Parkinson Disease.
+ Citations + Abstracts
1 Article Dl-3- 2019

Chen, Yajing / Wu, Tingting / Li, Heng / Li, Xuan / Li, Qing / Zhu, Xiaoying / Yu, Mei / Kuo, Sheng-Han / Huang, Fang / Wu, Yun-Cheng. ·Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. · Department of Neurology, Jinan Central Hospital Affiliated to Shandong University, Jinan, China. · The State Key Laboratory of Medical Neurobiology, The Institutes of Brain Science and the Collaborative Innovation Center for Brain Science, Shanghai Medical College, Fudan University, Shanghai, China. · Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, NY, United States. ·Front Aging Neurosci · Pubmed #30873019.

ABSTRACT: Microglia-mediated neuroinflammation contributes to multiple neurodegenerative disorders, including PD. Therefore, the regulation of microglial activation probably has the therapeutic potential. This study is aimed to determine whether NBP could suppress microglial activation and protect dopaminergic neurons from excessive neuroinflammation. In the present study, MPTP-induced PD model was established to explore the neuroprotective and anti-inflammatory effect of NBP. We assessed motor deficits, dopaminergic neurodegeneration and microglial activation in PD mice.

2 Article Therapeutic Potential of a Prolyl Hydroxylase Inhibitor FG-4592 for Parkinson's Diseases 2018

Li, Xuan / Cui, Xin-Xin / Chen, Ya-Jing / Wu, Ting-Ting / Xu, Huaxi / Yin, Huiyong / Wu, Yun-Cheng. ·Department of Neurology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. · Neuroscience Initiative, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA, United States. · Key Laboratory of Food Safety Research, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China. · Key Laboratory of Food Safety Risk Assessment, Ministry of Health, Beijing, China. · School of Life Sciences and Technology, ShanghaiTech University, Shanghai, China. ·Front Aging Neurosci · Pubmed #29755339.

ABSTRACT: As the main transcription factor that regulates the cellular responses to hypoxia, Hypoxia-inducible factor-1α (HIF-1α) plays an important role in the pathogenesis of Parkinson's disease (PD). HIF-1α is normally degraded through ubiquitination after hydroxylation by prolyl hydroxylases (PHD). Emerging evidence has suggested that HIF PHD inhibitors (HIF-PHI) may have neuroprotective effects on PD through increasing HIF-1α levels. However, the therapeutic benefit of HIF-PHI for PD remains poorly explored due to the lack of proper clinical compounds and understanding of the underlying molecular mechanisms. In this study, we examined the therapeutic benefit of a new HIF-PHI, FG-4592, which is currently in phase 3 clinical trials to treat anemia in patients with chronic kidney diseases (CKD) in PD models. FG-4592 attenuates MPP

3 Article Subcutaneous rotenone rat model of Parkinson's disease: Dose exploration study. 2017

Zhang, Zhen-Nian / Zhang, Jing-Si / Xiang, Jun / Yu, Zhong-Hai / Zhang, Wen / Cai, Min / Li, Xiang-Ting / Wu, Ting / Li, Wen-Wei / Cai, Ding-Fang. ·Department of Integrative Medicine, Zhongshan Hospital, Laboratory of Neurology, Institute of Integrative Medicine, Fudan University, 180 Fenglin Road, Shanghai 200032, China. · Department of Integrative Medicine, Zhongshan Hospital, Laboratory of Neurology, Institute of Integrative Medicine, Fudan University, 180 Fenglin Road, Shanghai 200032, China. Electronic address: dingfangcai@163.com. ·Brain Res · Pubmed #27876560.

ABSTRACT: Subcutaneous administration of rotenone has recently attracted attention because of its convenience, simplicity and efficacy in replicating features of Parkinson's disease (PD) in animal models. However, the wide range of doses reported in the literature makes it difficult to evaluate the effectiveness of this technique objectively. The aim of the present study was to identify the optimum dose of subcutaneous rotenone for establishing a model of PD. We injected male Wistar rats subcutaneously with one of three doses of rotenone (1.5, 2, or 2.5mg/kg) daily for 5 weeks. Rotenone caused a dose-dependent increase in α-synuclein in the substantia nigra. Furthermore, at 2 and 2.5mg/kg, rotenone caused a significant decrease in the number of tyrosine hydroxylase-immunoreactive neurons in the substantia nigra, and dopamine in the striatum. However, mortality at 2.5mg/kg was 46.7%, compared with just 6.7% at 2mg/kg; the high mortality observed at 2.5mg/kg would limit its application. The 2mg/kg dose showed no detrimental effect on body weight after 5 weeks of daily injections. Furthermore, rats in the 2mg/kg group showed a longer latency to descend from a horizontal bar and a grid wall, decreased rearing, and shorter latency to fall from a rotarod than rats that received vehicle or saline. Mitochondrial damage, observed by transmission electron microscopy, was also evident at this dose. Together, our data indicate that daily subcutaneous injection of 2mg/kg rotenone in rats facilitates the formation of α-synuclein and reproduces the typical features of PD, while maintaining low mortality.

4 Article Risk of lung cancer in Parkinson's disease. 2016

Xie, Xin / Luo, Xiaoguang / Xie, Mingliang / Liu, Yang / Wu, Ting. ·Department of Neurology, The First Affiliated Hospital of China Medical University, Shenyang City 110001, PR China. · Clinics of the People's Armed Police Command College, Tianjin City, 300000, PR China. ·Oncotarget · Pubmed #27801674.

ABSTRACT: Recently, growing evidence has revealed the significant association between Parkinson's disease (PD) and cancer. However, controversy still exists concerning the association between PD and lung cancer. A comprehensive article search for relevant studies published was performed using the following online databases: PubMed, Web of Science and Embase up to August 31, 2016. The pooled risk ratio (RR) and their 95 % confidence intervals (CI) were calculated using the method of inverse variance with the random-effects model. Fifteen studies comprising 348,780 PD patients were included in this study. The pooled result indicated that patients with PD were significantly associated with a decreased risk of lung cancer (RR: 0.53, 95% CI: 0.41-0.70, P < 0.001). In addition, subgroup analyses performed in Western population also confirmed the significant inverse relationship between PD and risk of lung cancer (RR: 0.48, 95% CI: 0.39-0.60, P < 0.001). In the subgroup analysis, a reduced risk of lung cancer in PD patients from Western population was consistent regardless of study design, gender, or study quality. In conclusion, PD patients were significantly associated with a reduced risk of lung cancer in Western population. The relationship between them in Asian population needs to be confirmed by future studies.